Physician profile
Amanda Crow
NPI 1407492861
$1,944.14
in general payments reported to CMS, 2019-2025
28 companies · $504 in 2025
The $504 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $573 · 2022: $376 · 2023: $324 · 2024: $167 · 2025: $504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $995.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $994.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $232.65 | 2021-2025 | Airsupra, Breztri |
| Novo Nordisk INC | $178.95 | 2022-2025 | Rybelsus, Ozempic |
| Amgen INC. | $168.36 | 2021-2025 | Otezla, Repatha |
| Abbvie INC. | $162.63 | 2022-2025 | |
| Esperion Therapeutics, INC. | $150.51 | 2021 | |
| Glaxosmithkline, LLC. | $139.83 | 2021-2024 | Shingrix, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $127.37 | 2021-2025 | |
| Lilly USA, LLC | $107.03 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $92.07 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Astellas Pharma US INC | $60.06 | 2022-2023 | Myrbetriq, Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.52 | 2022-2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.46 | 2021-2025 | Xifaxan |
| Amarin Pharma, INC. | $55.18 | 2021 | |
| Pfizer INC. | $50.96 | 2023-2025 | |
| Biohaven Pharmaceuticals, INC. | $43.55 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $30.40 | 2021 | |
| Idorsia Pharmaceuticals US INC | $28.61 | 2023 | Quviviq |
| Tactile Systems Technology INC | $27.55 | 2025 | Nimbl, Flexitouch Plus |
| Inspire Medical Systems, INC. | $22.79 | 2025 | Inspire |
| Boston Scientific Corporation | $22.01 | 2024 | |
| Cipher Pharmaceuticals US LLC | $20.94 | 2025 | Natroba, Spinosad |
| Hikma Pharmaceuticals USA | $18.34 | 2023 | Ryaltris |
| Genentech USA, INC. | $17.27 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.03 | 2022 | |
| Janssen Pharmaceuticals, INC | $16.18 | 2023 | Xarelto |
| Dexcom, INC. | $15.39 | 2024 | Dexcom G6 Transmitter |
| Antares Pharma, INC. | $14.21 | 2023 | Tlando, Xyosted, Nocdurna |
| Teva Pharmaceuticals USA, INC. | $11.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Crow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.